Syndax製藥 SNDX 深 滬
已收盤 04-02 16:00:00 美东时间
25.15
+1.270
+5.32%
華盛通- 最 高25.52
- 今 開23.44
- 成交量 209.37万股
- 最 低 23.21
- 昨 收 23.88
- 總市值 22.18亿
- 52周最高 25.59
- 市盈率 靜 --
- 換手率 2.37%
- 52周最低 8.58
- 委 比 65.85%
- 總股本 8820.06万
- 歷史最高 29.86
- 量 比 1.15
- 振 幅 9.67%
- 歷史最低 3.39
- 每 手 1
- 風險率 4.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Mizuho Maintains Outperform on Syndax Pharmaceuticals, Lowers Price Target to $43
Mizuho analyst Salim Syed maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Outperform and lowers the price target from $45 to $43.
03-31 21:30
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Damora Therapeutics appoints Jennifer Jarrett as President and CEO effective March 30, 2026. Jarrett, with nearly three decades of experience in biotech, tech, and finance, will also join the Board. Biotech leaders Cameron Turtle and Mike Landsittel are added to the Board, while Peter Harwin becomes Chairman. Damora aims to redefine care for blood disorder patients with innovative therapies targeting mutant calreticulin-driven MPNs. The new leade...
03-23 12:00
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify
U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify March 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Dow, Oracle and Shopify on Monday. HIGHLIGHTS * Dow Inc DOW.N : RBC raises to outperform from sector perform; raises PT t
03-09 15:34
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted stock options to three new employees under its 2023 Inducement Plan on March 1, 2026. The options cover up to 81,600 shares, vesting over four years with 25% after one year and the rest vesting monthly over 36 months. The company focuses on advancing innovative cancer therapies, including FDA-approved treatments Revuforj® and Niktimvo™.
03-04 21:01
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Citigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $57
Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $51 to $57.
03-03 03:19
财报速睇 | Syndax制药 2025财年Q4营收0.69亿美元，同比增长794.9%；归母净利润亏损0.68亿美元，同比亏损缩窄27.8%
华盛资讯2月27日讯，Syndax制药公布2025财年Q4业绩，公司Q4营收0.69亿美元，同比增长794.9%，归母净利润亏损0.68亿美元，同比亏损缩窄27.8%。
02-27 05:33
